

Caroline L Ng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1565594/publications.pdf>

Version: 2024-02-01

18
papers

1,098
citations

516710

16
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

1969
citing authors

#	ARTICLE	IF	CITATIONS
1	Animal models for SARS-CoV-2 research: A comprehensive literature review. <i>Transboundary and Emerging Diseases</i> , 2021, 68, 1868-1885.	3.0	58
2	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 613-623.	4.9	9
3	A Proteasome Mutation Sensitizes <i>P. falciparum</i> Cam3.11 K13 ^{C580Y} Parasites to DHA and OZ439. <i>ACS Infectious Diseases</i> , 2021, 7, 1923-1931.	3.8	6
4	Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). <i>Journal of Molecular Medicine</i> , 2020, 98, 1369-1383.	3.9	30
5	<i>Plasmodium falciparum</i> Artemisinin Resistance: The Effect of Heme, Protein Damage, and Parasite Cell Stress Response. <i>ACS Infectious Diseases</i> , 2020, 6, 1599-1614.	3.8	34
6	<i>Plasmodium falciparum</i> In Vitro Drug Resistance Selections and Gene Editing. <i>Methods in Molecular Biology</i> , 2019, 2013, 123-140.	0.9	21
7	Covalent <i>Plasmodium falciparum</i> -selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. <i>PLoS Pathogens</i> , 2019, 15, e1007722.	4.7	58
8	Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in <i>Plasmodium falciparum</i> that Confer In Vitro Resistance to the Clinical Candidate DSM265. <i>ACS Infectious Diseases</i> , 2019, 5, 90-101.	3.8	43
9	Defining the Determinants of Specificity of <i>Plasmodium</i> Proteasome Inhibitors. <i>Journal of the American Chemical Society</i> , 2018, 140, 11424-11437.	13.7	54
10	Antimalarial activity of single-dose DSM265, a novel <i>Plasmodium</i> dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated <i>Plasmodium falciparum</i> or <i>Plasmodium vivax</i> malaria infection: a proof-of-concept, open-label, phase 2a study. <i>Lancet Infectious Diseases</i> , 2018, 18, 874-883.	9.1	106
11	A potent antimalarial benzoxaborole targets a <i>Plasmodium falciparum</i> cleavage and polyadenylation specificity factor homologue. <i>Nature Communications</i> , 2017, 8, 14574.	12.8	110
12	Protein Degradation Systems as Antimalarial Therapeutic Targets. <i>Trends in Parasitology</i> , 2017, 33, 731-743.	3.3	46
13	Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity. <i>Nature Microbiology</i> , 2017, 2, 1403-1414.	13.3	47
14	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. <i>PLoS Medicine</i> , 2016, 13, e1002138.	8.4	35
15	CRISPR-Cas9 modified <i>pfmdr1</i> protects <i>Plasmodium falciparum</i> asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs. <i>Molecular Microbiology</i> , 2016, 101, 381-393.	2.5	56
16	A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. <i>Science Translational Medicine</i> , 2015, 7, 296ra111.	12.4	254
17	Supragenomic Network Compression and the Discovery of EXP1 as a Glutathione Transferase Inhibited by Artesunate. <i>Cell</i> , 2014, 158, 916-928.	28.9	113
18	UV-triggered Affinity Capture Identifies Interactions between the <i>Plasmodium falciparum</i> Multidrug Resistance Protein 1 (PfMDR1) and Antimalarial Agents in Live Parasitized Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 22576-22583.	3.4	18